Online citations, reference lists, and bibliographies.

Pelvic And Paraortic Lymph Nodal Status In Advanced Ovarian Cancer And Survival.

F. Parazzini, G. Valsecchi, G. Bolis, P. Guarnerio, S. Reina, G. Polverino, D. Silvestri
Published 1999 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND In order to analyze the prognostic role of node involvement in advanced ovarian cancer, we have analyzed data from a randomized clinical trial on advanced ovarian cancer. METHODS Cases were 456 women who entered a randomized multicentric clinical trial comparing two cisplatin-based schemes of treatment after cytoreductive surgery for advanced stage III-IV ovarian cancer. They underwent selective pelvic and/or paraortic lymphadenectomy. RESULTS A total of 161 (35.3%) cases had positive nodes. The frequency of positive nodes was statistically significantly higher in FIGO stage IV than in stage III. Also grade 3 tumors were more likely to have positive nodes than grade 1-2 tumors. No association was observed between nodal status and response to chemotherapy. The 3-year survival was 46.2 (standard error (SE) = 3.4 based on 147 deaths) and 44.6 (SE = 4.4, based on 84 deaths), respectively, in negative and positive node groups. The corresponding values, when the analysis was performed considering only subjects with residual tumor <1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE = 5.7) and 62.4 (SE = 9.6). CONCLUSIONS We did not find any association between nodal status and survival. Particularly, nodal status was not a prognostic factor for survival in the subgroup of women with residual tumor <1 cm or absent after cytoreductive surgery.
This paper references
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1016/0090-8258(91)90099-Q
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer
E. Burghardt (1991)
10.1111/j.1525-1438.1991.tb00028.x
Technique and feasibility of radical para-aortic and pelvic lymphadenectomy for gynecologic malignancies: a prospective study
Benedetti P. Panici (1991)
10.1002/(SICI)1097-0142(19960815)78:4<803::AID-CNCR17>3.0.CO;2-Z
Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma: A proposal for essential sites for lymph node biopsy
T. Onda (1996)
10.1006/gyno.1995.1058
Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer--therapeutic advance or surgical folly?
N. Hacker (1995)
10.1200/JCO.1997.15.5.1938
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
G. Bolis (1997)
10.1016/S0950-3552(89)80048-3
Pelvic and para-aortic lymphadenectomy in cancer of the ovary.
F. Di Re (1989)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
D. Cox (1972)
10.1038/bjc.1977.1
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
10.1046/j.1525-1438.1997.00418.x
Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease.
C. Scarabelli (1997)
10.1016/0020-7292(88)90037-9
Survival of ovarian carcinoma with or without lymph node metastasis
S. S. Chen (1987)



This paper is referenced by
10.1007/0-306-48388-2_15
Cancer Metastasis: Biological and Clinical Aspects, Gynaecological Cancer
M. Adams (2000)
10.1007/0-306-48388-2
Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention
W. Jiang (2000)
Prognostic signi fi cance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer
Suk-Joon Chang (2012)
10.1007/S10330-007-0092-6
Prognosis in epithelial ovarian cancer: Clinical analysis of 287 pelvic and para-aortic lymphadenectomy
Xiao-yun Yang (2007)
10.1007/s00761-007-1315-8
Operative Therapie beim Ovarialkarzinomrezidiv
J. Sehouli (2007)
10.1016/B978-0-323-40067-1.00011-5
11 – Epithelial Ovarian Cancer
E. Eisenhauer (2018)
10.1016/B978-0-443-07142-3.50033-6
Chapter 29 – Primary Surgery for Ovarian Cancer
J. Carter (2004)
10.6004/JNCCN.2011.0008
Epithelial ovarian cancer.
R. Morgan (2011)
10.1053/CTRV.2000.0196
The surgical management of ovarian cancer.
J. F. Stratton (2001)
10.1148/radiol.2541090361
Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging.
C. Mcmahon (2010)
10.1111/J.1447-0756.2010.01274.X
The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.
A. Abe (2010)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1053/BEOG.2002.0301
Role of lymphadenectomy in ovarian cancer.
P. Panici (2002)
10.1186/1477-7819-2-32
Role of primary surgery in advanced ovarian cancer
K. Münstedt (2004)
10.1159/000063805
Prognostic Factors of Secondary Ovarian Carcinoma
F. Kikkawa (2002)
10.1016/B978-0-323-07419-3.00011-4
Chapter 11 – Epithelial Ovarian Cancer
E. Eisenhauer (2012)
10.6118/jmm.2014.20.1.43
Perimenopausal Ovarian Carcinoma Patient with Subclavian Node Metastasis Proven by Immunohistochemistry
Hee Jeong Jeong (2014)
10.1002/JSO.10124
Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
U. Saygılı (2002)
10.1016/S0021-7697(08)45009-3
Place du curage lombo-aortique et pelvien dans les cancers épithéliaux de l’ovaire
D. Salet-Lizée (2008)
10.1016/J.YGYNO.2005.06.051
Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
N. Takeshima (2005)
10.3892/ol.2014.2820
Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report
Shigao Huang (2015)
10.1080/00016340802478158
Significance of preoperative serum CA‐125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer
H. S. Kim (2008)
10.1186/s13048-020-00653-4
The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials
Qingqing Lin (2020)
10.1016/j.ygyno.2012.05.014
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Suk-Joon Chang (2012)
10.1016/j.ejrad.2011.01.112
Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis.
Y. Yuan (2012)
10.1016/B978-032303978-9.50014-9
Chapter 11 – Epithelial Ovarian Cancer
L. Copeland (2007)
Aktuelle Aspekte der Behandlung und Nachsorge von Patientinnen mit fortgeschrittenem Ovarialkarzinom
Werner Lichtenegger (2010)
Polymorphism and expression of IL-10 in serum and ascites from patients with advanced ovarian cancer
Elena Ioana Braicu (2011)
10.1136/ijgc-2019-000310
Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer
Ingrid Lai (2019)
10.1007/s10147-007-0672-z
Management of retroperitoneal lymph nodes in the treatment of ovarian cancer
K. Ushijima (2007)
10.5812/ircmj.10758
The Effect of Extrafascial Hysterectomy After Completion of External Beam Radiotherapy for Treatment of Locally Advanced Stages (IIB-III) of Cervical Cancer
Zahra Sarraf (2013)
Surgery remains key in the diagnosis , staging , and management of ovarian cancer . The Role of Surgery in the Management of Epithelial Ovarian Cancer
Ingrid Ramírez (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar